Paolo Tarantino, MD, of Dana-Farber Cancer Institute, shows that antibody-drug conjugate (ADC) resistance appears to be driven by complex molecular adaptations beyond target modulation.
It will have the opportunity to present the results from Charisma, which was a project where basically we aim to unveil resistance mechanisms to novel ADCs. We're using now nowadays ADCs to treat every type of cancer, but in breast oncology, we have 4 ADCs approved, of which 3 are basically topo topoinhibitor 1 based ADCs. They deliver chemotherapy by targeting. Either HERS 2 and THRP 2 and delivering a toposomers 1 inhibitor. And now, in truth, we don't know exactly how tumor cells become, uh, let's say, evade treatment with these agents. And so we developed this project where basically we would, we, we would collect prospectively biopsy samples uh before and after a disease, but also utilize retrospective collections and perform uh in centralized manner in a partnership with AstraZeneca, NGS profiling, uh, immunohistochemistry, and mass spectrometry profiling of all of these biopsies and comparing basically the findings before and after the ADC to see what changes over time. And what we found is that something that has been described before, a down regulation of the receptor, kind of happens with TDXT. Among 14 patients treated with TDXT, about half had a decrease in HERS2, but all of them had some degree of HERS2 that was retained. And actually with the other ADC we studied, sacituza and Govitikin, we didn't really see a consistent down regulation of the target. And so overall resistance does not appear to be clearly associated with the down regulation of the target, but we did see instead some genetic alteration. which emerged after treatment with ADCs. There were 3 patients which developed acquired TP53 mutations which potentially could be associated with resistance. We also saw that there were 3 patients with acquired ABCB1 and ABCC1 acquired copy number gains or amplifications, and we know that these are important e-flux pumps that can Lead to resistance to the chemotherapy backbone. To further confirm that, we compared the mass spectrometry evaluation of these pumps, and we saw that in most of the samples, once again, there was up regulation of either ABCC1 or ABCB1 or both. And finally, we looked also at some additional proteins, one in particular, man 2A2, related to glycosylation that seems to be Down regulated after progression on TDXT. All of this, of course, is hypothesis generating. We try to confirm some of this in preclinical models. And so when we, when we um uh induce or expression of influx pumps in preclinical models, this led to decreased sensitivity to TDXT, decreased payload exposure. And when instead in another model, We silence man 2A2, this led to decreased TDXC binding and internalization. And so I do think what we are learning from this work and also from the all the amount of work done in this field is that ADC resistance appears multifactor. is clearly not just related to down regulation of the target, but also to increased drug influx, impaired internalization and binding of ADCs, and multiple features that concomitantly can lead to resistance to ADCs.